Trial of CTX 1301 for the treatment of Attention Deficit Hyperactivity Disorder (ADHD)

Trial Profile

Trial of CTX 1301 for the treatment of Attention Deficit Hyperactivity Disorder (ADHD)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs CTX 1301 (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Pharmacokinetics; Proof of concept
  • Most Recent Events

    • 10 Jul 2017 Status changed from recruiting to completed, according to a Cingulate Therapeutics media release.
    • 31 May 2017 According to a Cingulate therapeutics media release, dosing has been initiated in this trial, and the company anticipates reporting findings from this trial in the third quarter of 2017.
    • 24 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top